There are currently 380 clinical trials in Scottsdale, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Arizona, Mayo Cliinic - Scottsdale, Mayo Clinic and Mayo Clinic Arizona. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Recruiting
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to a limited number of sites (oligometastatic). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the bo... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
The CONFORM Pivotal Trial
Recruiting
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: HonorHealth, Scottsdale, Arizona
Conditions: Atrial Fibrillation, Stroke
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Recruiting
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
01/06/2025
Locations: KalVista Investigative Site, Scottsdale, Arizona
Conditions: Hereditary Angioedema
A Clinical Study to Evaluate DNTH103 in Adults with Multifocal Motor Neuropathy
Recruiting
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with multifocal motor neuropathy (MMN).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/06/2025
Locations: Clinical Study Site, Scottsdale, Arizona
Conditions: Multifocal Motor Neuropathy
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
Recruiting
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study will be conducted in 2 sequential parts. Up to 36 subjects diagnosed with IFALD will be enrolled in the study, of which up to 18 subjects will be enrolled in each of the 2 parts and randomized (2:1) t... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/05/2025
Locations: Mayo Clinic Scottsdale Campus, Scottsdale, Arizona
Conditions: Intestinal Failure Associated Liver Disease
ORB-021 In Patients With Advanced Solid Tumors
Recruiting
The goal of this clinical research study is to determine if an investigational new drug, named ORB-021, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Honor Health Clinical Research, Scottsdale, Arizona
Conditions: Advanced Solid Tumors Cancer
A Collaborative Intervention for Improving Cancer Pain Management in Rural and Hispanic Cancer Survivors (ASCENT)
Recruiting
This clinical trial tests a collaborative pain management intervention (ASCENT) for improving cancer pain in rural and Hispanic cancer survivors. Cancer pain is prevalent, under-treated, and remains a major cause of suffering, impairment, and disability for millions of Americans. Individual pain interventions and care models show promise for cancer pain in controlled settings. Hispanic and rural-dwelling cancer survivors stand to benefit the most from electronic health record innovations, as eac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II
Recruiting
To demonstrate the safety and effectiveness of the Reducer system for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization. A non-randomized single-arm will further assess the safety and effectiveness of the Neovasc Reducer System in selected subjects with rever... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Refractory Angina
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Recruiting
This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in the world. Liver transplantation is a potentially curative treatment option for HCC, however, up to 20% of patients develop recurrent disease after liver transplantation and prognosis remains poor. Lenvatinib may stop the growth of tumor cells by blocking some... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Mayo Clinic Arizona, Scottsdale, Arizona
Conditions: Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Recruiting
This phase II trial tests how well abiraterone acetate/niraparib (CJNJ-67652000 \[niraparib/abiraterone acetate fixed-dose combination\]) and prednisone works in treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and who have a mutation in the SPOP gene. CJNJ-67652000 (niraparib/abiraterone acetate fixed-dose combination) is a drug which stops certain cancer cells from being able to repai... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Cardiac Rehabilitation Mobile-Health Fall Risk Prevention Intervention
Recruiting
The purpose of this research is to see if taking part in a structured exercise plan that is designed to improve balance and muscle strength and one that can done at home helps to improve the ability to perform standard physical tasks, confidence in balance, and health-related quality-of-life
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Mayo Clinic Arizona, Scottsdale, Arizona
Conditions: Cardiac Rehabilitation
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy
Recruiting
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
Gender:
ALL
Ages:
30 years and above
Trial Updated:
12/20/2024
Locations: Movement Disorders Center of Arizona, Scottsdale, Arizona
Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy